Colorectal Cancer

From cancer to COVID-19, our patient stories can help others take sickness and disease seriously.

Keytruda bested chemotherapy, delaying disease progression or death by 40%, in a clinical trial that led to the drug’s approval for use as a single initial treatment for patients with colorectal cancer.

Andrea Dwyer spoke with CURE® about the symposium and why it is important to raise global awareness around the increasing rate of early-age onset colorectal cancer.

Multitasking isn't an exact science and its ok, often better, to take things one at a time on the cancer journey.

Today, during Young Survivors Week, national leading non-profit Colorectal Cancer Alliance released findings from its latest survey of young-onset colorectal cancer patients and survivors.

Childhood cancer survivors are developing colorectal polyps unrelated to family histories, according to new data.

While follow-up data on the BEACON CRC study demonstrated superior overall survival for certain patients with metastatic colorectal cancer receiving Braftovi, Mektovi and Erbitux, an exploratory analysis is needed to understand if this treatment can impact a wider subset of patients.

“These long-awaited trial results will change clinical practice,” lead study author Dr. Thierry André, of the Sorbonne Université and Hôpital Saint Antoine in Paris, said in an ASCO-issued press release.

As the risk of colorectal cancer grows among those under 50, younger adults should know more about signs and screening.

People experiencing gastrointestinal symptoms or delays in colorectal cancer care should address these questions with their care team.

The Braftovi-Erbitux combination will become the preferred second-line treatment option in treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, according to one expert.

Despite the impact that COVID-19 is having on cancer treatment schedules, one expert stresses the importance of staying the course not just for an individual’s benefit, but for the health of others.

From a woman with stage 4 colon cancer deciding to stream her wedding on Zoom to a patient with breast cancer sewing masks for at-risk groups across the United States, here’s the cancer news and updates happening amid the COVID-19 pandemic.

The Food and Drug Administration approved the combination use of Braftovi plus Erbitux for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation.

Although the absolute risk for colorectal cancer is very low for young people, one expert warns the incidence is increasing.

Most people are in the dark about Lynch syndrome, a not uncommon condition that predisposes individuals to cancer. Patient advocacy group AliveAndKickn works to illuminate the issue.

What happens to the American man -- one who has been taught there is no hurdle he can't handle on his own -- when a challenge comes along that he can't simply fix?

The one-of-a-kind resource at LivingWithLynch.org offers voices of hope in the face of a Lynch syndrome diagnosis on Lynch Syndrome Awareness Day, March 22, 2020.

Here is a list of the recent trial initiations that occurred within the cancer space in February.

51% of Americans 50-54 have not been screened for colorectal cancer. We know screening saves lives, here's why.

On every cancer journey we need a strong support group to provide strength, acceptance and love — for one patient with cancer their spouse stepped into that role and beyond.

New research examining Surveillance, Epidemiology, and End Results (SEER) program data found that relying solely on this data may lead to underestimating the rising rate of colorectal cancer in patients aged 49 and 50.

Although the rate of colorectal and gastric cancers has decreased in the overall population, new study findings show a rise in young adults.

The cancer landscape has changed for patients with the introduction of targeted therapies, and a combination targeted therapy for some patients with colorectal cancer shows new promise.

Nature can provide a new perspective on one's cancer journey.